从大型心血管转归研究解读二肽激肽酶Ⅳ抑制剂的心血管安全性被引量：2

导出

摘要降血糖药与心血管不良事件的关系近年来日益受到关注。美国食品和药品监督管理局（FDA）于2008年正式出台了相关的指导原则，要求所有新的降糖药必须评估其心血管安全性。因此，多种新型降糖药二肽激肽酶Ⅳ（DPP？4）抑制剂类药物纷纷开展了心血管转归的临床试验，其中两项大型临床试验--“阿格列汀与标准疗法对近期发生急性冠状动脉综合征（ACS）的2型糖尿病患者（T2DM）心血管安全性的影响比较”（EXAMINE研究，NCT00968708）和“T2DM患者使用沙格列汀的心血管结果评估”（SAVOR研究，NCT01107886）的结果率先于2013年发表。本文主要通过解读大型心血管转归临床研究来探讨DPP？4抑制剂的心血管安全性。

作者李焱

机构地区中山大学附属第二医院内分泌科

出处《中华糖尿病杂志》 CAS CSCD 2015年第5期334-336,共3页 CHINESE JOURNAL OF DIABETES MELLITUS

关键词二肽激肽酶Ⅳ抑制剂心血管安全性转归解读急性冠状动脉综合征大型临床试验心血管不良事件药品监督管理局

分类号 R587.1 [医药卫生—内分泌]

引文网络
相关文献

参考文献20

1The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes [J]. N Engl J Med,2008,358(24):2560-2572.
2Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes[J]. N Engl J Med,2009,360(2):129-139.
3Selvin E, Steffes MW, Zhu H, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults[J]. N Engl J Med,2010,362(9):800-811.
4Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non- insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS:23) [J]. BMJ,1998,316(7134): 823-828.
5The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus[J]. N Engl J Med,1993, 329(14):977-986.
6Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes[J]. N Engl J Med, 2008, 359(15):1577-1589.
7Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes [J]. N Engl J Med,2008,358(24):2545-2559.
8ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes [J]. N Engl J Med,2008,358(24):2560-2572.
9Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes[J]. N Engl J Med,2009,360(2): 129-139.
10Guidance for industry: diabetes mellitus - - evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. U.S. Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER), December 2008.[2011 - 10 - 18]http://www. fda.gov/downloads/Drugs/ GuidanceComplianceRegulatorylnformation/Guidances/ ucm071627.pdf.

<12 >

同被引文献35

1Feinglos MN,Bethel MA. Therapy of type 2 diabetes,cardiovascular death, and the UGDP[J}. Am Heart J, 1999,138(5 Pt l):S346-352.
2Nissen SE, Wolski K. Effect of rosiglitazone on the risk ofmyocardial infarction and death from cardiovascular causes[J].N Engl J Med, 2007,356(24):2457-2471 .DOI: 10.1056/NEJMoa072761.
3Burke MA, Mutharasan RK, Ardehali H. The sulfonylureareceptor, an atypical ATP- binding cassette protein, and itsregulation of the KATP channel[J]. Circ Res, 2008, 102(2):164-176. DOI: 10.1161/CIRCRESAHA.107.165324.
4Intensive blood-glucose control with sulphonylureas or insulincompared with conventional treatment and risk ofcomplications in patients with type 2 diabetes (UKPDS 33).UK Prospective Diabetes Study (UKPDS) Group[J]. Lancet,1998,352(9131):837-853.
5Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up ofintensive glucose control in type 2 diabetes[J]. N Engl J Med,2008,359(15):1577-1589. DOI: 10.1056/NEJMoa0806470.
6Patel A, MacMahon S, Chalmers J, et al. Intensive bloodglucose control and vascular outcomes in patients with type 2diabetes[J]. N Engl J Med, 2008,358(24):2560-2572. DOI:10.1056/NEJMoa0802987.
7Panicker GK, Kamad DR, Salvi V,et al. Cardiovascular riskof oral antidiabetic drugs: current evidence and regulatoryrequirements for new drugs[J], J Assoc Physicians India, 2012,60:56-61.
8Schramm TK, Gislason GH,Vaag A,et al. Mortality andcardiovascular risk associated with different insulinsecretagogues compared with metformin in type 2 diabetes,with or without a previous myocardial infarction: a nationwidestudy[J]. Eur Heart J, 2011,32(15):1900-1908. DOI: 10.1093/eurheartj/ehr077.
9Effect of intensive blood- glucose control with metformin oncomplications in overweight patients with type 2 diabetes(UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group[J]. Lancet, 1998,352(9131):854-865.
10Garber AJ, Abrahamson MJ, Barzilay JI, et al. AmericanAssociation of Clinical Endocrinologists' comprehensivediabetes management algorithm 2013 consensus statement-executive summary[J]. Endocr Pract, 2013,19(3):536-557.DOI: 10.4158/EP13176.CS.